Baxter Sigma Spectrum Infusion Pump Recall: Alarm Failure Linked To At Least Three Deaths

An alarm may fail to warn of an upstream occlusion indicating the flow of drugs or fluids is blocked.

More than a quarter million Baxter Sigma Spectrum infusion pumps are being recalled after at least three patients died due to an alarm failure.

The FDA announced the Sigma Spectrum Infusion Pump recall on March 11, giving it a class I designation; meaning the agency feels the problems with the infusion pump are likely to cause significant injuries or deaths. Baxter Healthcare, the manufacturer, has already reported it has received 51 reports of serious injuries and three patient deaths over the last five years due to problems with the recalled infusion pumps.

The recalled devices are software-controlled infusion pumps which deliver fluid drugs or blood products directly into patients’ veins while they are in the hospital or another healthcare facility. However, according to Baxter, the devices can fail to issue an alarm for repeated upstream occlusion event, which occurs when the flow of fluids is blocked.

MEDTRONIC MINIMED LAWSUITS

Did you or a loved one receive a Medtronic MiniMed insulin pump?

Recalled Medtronic MiniMed insulin pumps have been linked to reports of hypoglycemia, hyperglycemia and other serious injuries.

Learn More About this Lawsuit SEE IF YOU QUALIFY FOR COMPENSATION

If the occlusion event is not resolved, the alarm will not sound again for the remainder of that infusion. The device may appear to be functioning normally, but may be infusing below the programmed rate or not at all, meaning patients are not getting their full dosage and may not be receiving crucial medical care.

The recall affects Baxter Sigma Spectrum Infusion Pumps with Master Drug Library (Version 8) with product code 35700BAX2, and Spectrum IQ Infusion Systems with Dose IQ Safety Software (Version 9) with product code 3570009. The recalled devices were distributed from February 5, 2015 to present.

The recall affects an estimated 277,450 devices sold throughout the United States.

Baxter first warned its customers of the problem in an Urgent Safety Communication in late December, according to the FDA, urging clinicians to be aware of the problem and giving them specific instructions on how to watch for it, and what to do if the situation occurs.

Customers with questions are asked to contact their Baxter Sales Representative, or Baxter Technical Assistance at 800-356-3454.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

First Gardasil Lawsuit Set For Trial To Begin October 7th in California State Court
First Gardasil Lawsuit Set For Trial To Begin October 7th in California State Court (Posted today)

The first Gardasil lawsuit will go to trial in California state court in October, as a group of cases at the federal level continue to be developed for future bellwether trials that are unlikely to begin until late 2025 or early 2026.

Tepezza Settlement Talks For Hearing Loss Claims Will Commence Next Month
Tepezza Settlement Talks For Hearing Loss Claims Will Commence Next Month (Posted today)

Parties have been directed to meet quarterly for mediation sessions, which will explore the potential for Tepezza hearing loss settlements, as the talks leading up to the first bellwether trials, slated to begin in March 2026.

Judge Allows New Ozempic, Wegovy Lawsuits To Be Directly Filed in Federal MDL
Judge Allows New Ozempic, Wegovy Lawsuits To Be Directly Filed in Federal MDL (Posted yesterday)

A federal judge is allowing those presenting Ozempic, Wegovy and Mounjaro lawsuits to file them directly with the MDL court to speed up the process of preparing the cases for potential future bellwether trials.